menu ☰
menu ˟

Pioglitazone improves NASH, reduces fibrosis in type 2 diabetes

13 Dec 2017
Pioglitazone effectively reduced nonalcoholic fatty liver disease activity score in patients with nonalcoholic steatohepatitis with and without type 2 diabetes, according to a recently published study. Pioglitazone also reduced liver fibrosis in pati...

Click here to view the full article which appeared in Endocrinology

IPH Logo